Refine by
Cytology Articles & Analysis
32 articles found
Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for its cutting-edge preclinical alfaCAR-T solutions. ...
Alfa Cytology has revealed new FAP-targeted therapeutics development services that aim to develop precise and effective cancer treatments. Alfa Cytology has introduced its groundbreaking initiative which targets fibroblast activation protein(FAP) for cancer therapies. ...
Alfa Cytology has officially released its antibody-drug conjugates(ADCs) development services which demonstrates the dedication to fighting cancer through advanced treatment methods. ...
In recent years, the fight against cancer has seen significant advances, particularly with the emergence of targeted therapy. Among the most promising strategies in this domain is the development of radioactive drug conjugates(RDCs). These innovative therapeutic agents combine the targeting capabilities of antibodies with the cytotoxic effects of radioactive isotopes, providing a powerful ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. ...
In the ever-evolving landscape of cancer research, two intriguing concepts have emerged that are reshaping how scientists approach treatment: synthetic lethality and parthanatos. Both concepts encapsulate the complexity of cellular processes and open new avenues for targeted therapies. What is Synthetic Lethality? Synthetic lethality occurs when the simultaneous disruption of two genes ...
Alfa Cytology unveils advanced cancer immunotherapy development services. Alfa Cytology, a renowned services supplier in oncology, has recently introduced its groundbreaking cancer immunotherapy development services. ...
Alfa Cytology has launched ovarian cancer therapy development services. Alfa Cytology, a prominent services provider in oncology, has launched its cutting-edge ovarian cancer therapy development services. ...
Leukemia, a malignant disorder of the blood and bone marrow, poses significant challenges to both patients and healthcare providers. Traditional treatments, including chemotherapy and radiation, while effective for some, often come with severe side effects and varied success rates. Enter immunotherapy - a groundbreaking approach that is not only redefining leukemia treatment but also offering ...
Alfa Cytology introduces comprehensive small molecule PARPi development services for combating various diseases. Alfa Cytology, a developer of oncology innovation, has announced its latest venture small molecule Poly(ADP-ribose) polymerase inhibitor development services. ...
Alfa Cytology has unveiled new services focused on therapeutic antibody development for bladder cancer research.Alfa Cytology, a prominent cancer research services supplier based in New York, proudly announces the launch of its comprehensive services for bladder cancer therapeutic antibody development. ...
Breast cancer remains one of the most prevalent malignancies affecting women worldwide, necessitating innovative approaches for effective treatment and research. Among the most promising strategies in this endeavor are the use of tumor models for breast cancer and the development of customized antibody-drug conjugates (ADCs). These advancements not only enhance our understanding of the disease ...
Alfa Cytology has introduced its advanced drug development services for brain tumors. ...
Peptidomimetics are structural analogs of peptides or proteins that mimic their biological activities. They are designed to overcome limitations associated with peptides, such as poor stability and bioavailability by preserving or enhancing their functions. Peptidomimetic development involves the design and synthesis of molecules that mimic three-dimensional structures and functional groups of ...
Alfa Cytology has announced cancer diagnostic biomarker development services to enhance precision in oncology research. ...
Whether pathologic research or therapeutics development, CD BioSciences practically has experienced cytology experts with advanced equipment and tech to accelerate research progress. ...
Cancer is a daunting diagnosis; however, the rapid advancements in oncology are continuously perfecting patient outcomes and quality of life. Among the groundbreaking developments, cancer vaccines are a promising frontier1. These vaccines are transforming how we approach cancer treatment, leveraging the body's immune system to fight malignancies more effectively. To grasp how cancer vaccines ...
Brain tumors can be broadly categorized into primary and secondary (or metastatic) tumors. Primary tumors originate in the brain1, while secondary tumors spread from other body parts. Treatment options traditionally include surgery, radiation therapy, and chemotherapy. However, these approaches can be invasive and have severe side effects. The battle against brain tumors is being ...
Alfa Cytology has announced pancreatic cancer vaccine development services to improve the efficacy and safety of related vaccines. ...
Breast cancer is a type of cancer that begins in the cells of the breast. It can occur in both men and women but is more common in women. Breast cancer can develop in different parts of the breast, including the tubes that carry milk to the nipple or the lobules that produce milk. The exact cause of breast cancer is not completely understood, but factors such as genetics, hormone situations, ...